Homologous restriction factor: effect on complement C8 and C9 uptake and lysis. 1994

L S Zalman, and H Müller-Eberhard
Department of Immunology, Scripps Research Institute, La Jolla, CA 92037.

Homologous restriction factor (HRF) is a complementary regulatory protein found on the surface of human erythrocytes and other cell types. It has the function of blocking the lytic action of the membrane attack complex (MAC) of complement when incorporated into a membrane. HRF was found to inhibit not only the MAC composed of the proteins C5b-9, but also the C5b-8 complex. When 125I-labelled HRF was allowed to insert into an erythrocyte target, lysis by C5b-8 was reduced by about 80%. When human erythrocytes were treated with antibody to HRF, which bound to and presumably blocked the action of HRF, lysis by C5b-8 increased. This increase was not caused by additional binding of C8 on the cell membrane. When HRF was inserted into a target cell membrane, it had the effect of reducing the amount of C9 that could bind to very low levels, in one experiment from 6000 molecules per cell to about 500 molecules per cell. When this value was compared to the number of C7 molecules that bound, it was found that HRF reduced the amount of C9 bound to the level of C7 that was bound. HRF seemed to reduce the number of molecules of C9 that could bind to the C5b-8 complex so that only one C9 bound per complex.

UI MeSH Term Description Entries
D001798 Blood Proteins Proteins that are present in blood serum, including SERUM ALBUMIN; BLOOD COAGULATION FACTORS; and many other types of proteins. Blood Protein,Plasma Protein,Plasma Proteins,Serum Protein,Serum Proteins,Protein, Blood,Protein, Plasma,Protein, Serum,Proteins, Blood,Proteins, Plasma,Proteins, Serum
D002352 Carrier Proteins Proteins that bind or transport specific substances in the blood, within the cell, or across cell membranes. Binding Proteins,Carrier Protein,Transport Protein,Transport Proteins,Binding Protein,Protein, Carrier,Proteins, Carrier
D003165 Complement System Proteins Serum glycoproteins participating in the host defense mechanism of COMPLEMENT ACTIVATION that creates the COMPLEMENT MEMBRANE ATTACK COMPLEX. Included are glycoproteins in the various pathways of complement activation (CLASSICAL COMPLEMENT PATHWAY; ALTERNATIVE COMPLEMENT PATHWAY; and LECTIN COMPLEMENT PATHWAY). Complement Proteins,Complement,Complement Protein,Hemolytic Complement,Complement, Hemolytic,Protein, Complement,Proteins, Complement,Proteins, Complement System
D003185 Complement C8 A 150-kDa serum glycoprotein composed of three subunits with each encoded by a different gene (C8A; C8B; and C8G). This heterotrimer contains a disulfide-linked C8alpha-C8gamma heterodimer and a noncovalently associated C8beta chain. C8 is the next component to bind the C5-7 complex forming C5b-8 that binds COMPLEMENT C9 and acts as a catalyst in the polymerization of C9. C8 Complement,Complement 8,Complement Component 8,Complement Component C8 alpha,Complement Component C8 alpha Chain,Complement Component C8 beta,Complement Component C8 beta Chain,Complement Component C8 gamma,Complement Component C8 gamma Chain,C8, Complement,Complement, C8,Component 8, Complement
D003186 Complement C9 A 63-kDa serum glycoprotein encoded by gene C9. Monomeric C9 (mC9) binds the C5b-8 complex to form C5b-9 which catalyzes the polymerization of C9 forming C5b-p9 (MEMBRANE ATTACK COMPLEX) and transmembrane channels leading to lysis of the target cell. Patients with C9 deficiency suffer from recurrent bacterial infections. C9 Complement,Complement 9,Complement Component 9,C9, Complement,Complement, C9,Component 9, Complement
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004910 Erythrocyte Membrane The semi-permeable outer structure of a red blood cell. It is known as a red cell 'ghost' after HEMOLYSIS. Erythrocyte Ghost,Red Cell Cytoskeleton,Red Cell Ghost,Erythrocyte Cytoskeleton,Cytoskeleton, Erythrocyte,Cytoskeleton, Red Cell,Erythrocyte Cytoskeletons,Erythrocyte Ghosts,Erythrocyte Membranes,Ghost, Erythrocyte,Ghost, Red Cell,Membrane, Erythrocyte,Red Cell Cytoskeletons,Red Cell Ghosts
D006461 Hemolysis The destruction of ERYTHROCYTES by many different causal agents such as antibodies, bacteria, chemicals, temperature, and changes in tonicity. Haemolysis,Extravascular Hemolysis,Intravascular Hemolysis,Extravascular Hemolyses,Haemolyses,Hemolyses, Extravascular,Hemolyses, Intravascular,Hemolysis, Extravascular,Hemolysis, Intravascular,Intravascular Hemolyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

L S Zalman, and H Müller-Eberhard
March 1990, Journal of immunological methods,
L S Zalman, and H Müller-Eberhard
July 2005, Xenotransplantation,
L S Zalman, and H Müller-Eberhard
August 1981, Proceedings of the National Academy of Sciences of the United States of America,
Copied contents to your clipboard!